ARWR VS ITGR Stock Comparison
Performance
ARWR10/100
10/100
ARWR returned -18.45% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
ITGR100/100
100/100
ITGR returned 22.63% in the last 12 months. Based on SPY's performance of -13.32%, its performance is above average giving it a score of 100 of 100.
Analyst Price Targets
ARWR63/100
63/100
4 analysts offer 12-month price targets for ARWR. Together, they have an average target of 63.86, the most optimistic target put ARWR at 90 within 12-months and the most pessimistic has ARWR at 31.
ITGR65/100
65/100
5 analysts offer 12-month price targets for ITGR. Together, they have an average target of 0, the most optimistic target put ITGR at 0 within 12-months and the most pessimistic has ITGR at 0.
Technicals
ARWR64/100
64/100
ARWR receives a 64 of 100 based on 14 indicators. 8 are bullish, 4 are bearish.
ITGR89/100
89/100
ITGR receives a 89 of 100 based on 14 indicators. 12 are bullish, 1 are bearish.
Earnings
ARWR10/100
10/100
ARWR has missed earnings 16 times in the last 20 quarters.
ITGR44/100
44/100
ITGR has missed earnings 3 times in the last 20 quarters.
Profit
ARWR24/100
24/100
Out of the last 20 quarters, ARWR has had 6 profitable quarters and has increased their profits year over year on 2 of them.
ITGR71/100
71/100
Out of the last 20 quarters, ITGR has had 20 profitable quarters and has increased their profits year over year on 7 of them.
Volatility
ARWR50/100
50/100
ARWR has had a higher than average amount of volatility over the last 12 months giving it a score of 50 of 100.
ITGR49/100
49/100
ITGR has had a lower than average amount of volatility over the last 12 months giving it a score of 49 of 100.
All score calculations are broken down here to help you make more informed investing decisions
Arrowhead Research Corporation Summary
Nasdaq / ARWR
Healthcare
Biotechnology
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
Integer Holdings Corporation Summary
New York Stock Exchange / ITGR
Healthcare
Medical - Devices
Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through Medical and Non-Medical segments. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, urology, and gastroenterology procedures. It also provides cardiac rhythm management products, including implantable pacemakers, implantable cardioverter defibrillators, insertable cardiac monitors, implantable cardiac pacing and defibrillation leads, and heart failure therapies; neuromodulation products, such as implantable spinal cord stimulators; and non-rechargeable batteries, feedthroughs, device enclosures, machined components, and lead components and sub-assemblies. In addition, the company offers rechargeable batteries and chargers; and arthroscopic, laparoscopic, and general surgery devices and components, such as harmonic scalpels, shaver blades, burr shavers, radio frequency probes, biopsy probes, trocars, electrocautery components, wound dressings, GERD treatment components, and phacoemulsification needles. Further, it provides orthopedic products that include instruments used in hip, knee, and spine surgeries, as well as reamers and chisels. Additionally, the company offers customized battery power and power management systems, and battery solutions for the energy, military, and environmental markets. Furthermore, the company provides medical technologies. It serves multi-national original equipment manufacturers and their affiliated subsidiaries in the cardiac, neuromodulation, orthopedics, vascular, and advanced surgical and portable medical markets. Integer Holdings Corporation was founded in 1970 and is headquartered in Plano, Texas.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare ARWR to other companies in the same or a similar industry.